Skip to content

Esketamine research published in 2025

Page 12 of 13: studies 221 to 240 of 244, newest first. Back to the esketamine overview

Studies

Research trends in esketamine for depression over the past decade: a bibliometric analysis.

Frontiers in Psychiatry 2025 Baozhou Zhang, Yifan Liu, Jinwei Zheng et al. 1 citation

Patients suffering from depression frequently encounter extended periods of low moods and lack of enjoyment or enthusiasm for activities. It leads to suicidal thoughts and presents a potential hazard to their safety. Nowadays, there has been significant progress in researching the effectiveness and safety of esketamine in treating depression. Hence, this paper employs bibliometric analysis to...

DOI: 10.3389/fpsyt.2025.1621830 (opens in new tab) Full text (opens in new tab) Bibliometric analysis Research trend Esketamine research esketamine Studies +9

Ketamine for mood disorders, anxiety, and suicidality in children and adolescents: a systematic review.

European Child & Adolescent Psychiatry 2025 Alisha M Bruton, Dalton G Wesemann, Taryn A Machingo et al. 20 citations

Mood disorders, anxiety, and suicidality in youth are increasing and rapid-acting treatments are urgently needed. One potential is ketamine or its enantiomer esketamine, which was FDA approved in 2019 to treat major depressive disorder with suicidality in adults. This systematic review evaluated the evidence for the clinical use of ketamine to treat mood disorders, anxiety, and suicidality in...

Adjunctive Intranasal Esketamine for Comorbid Treatment-Resistant Depression with Suicidal Ideation in Patients Receiving Palliative Care at a Comprehensive Cancer Center: A Case Series.

Journal of Palliative Medicine 2025 Mercy Tomy, William B Alexander, Sanjay Gupta et al. 4 citations

Background: The psychiatric needs of those with cancer and other advanced illnesses are becoming increasingly recognized. Ketamine is emerging as a promising treatment option for depressive disorders in psychiatric and palliative care. In the palliative care setting, its study has been hindered by lack of consistent administration routes and dosing. Intranasal (IN) esketamine (Spravato®) has...

Compassionate use of esketamine intranasal in patients with severe major depressive disorder resistant to the treatment.

Journal of Psychopharmacology 2025 Luis Gutiérrez-Rojas, Julia Vendrell-Serres, Josep Antoni Ramos‐quiroga et al. 8 citations

Treatment-resistant depression (TRD) is defined as the failure of at least two antidepressants in adequate doses and timing during a major depressive episode. Esketamine intranasal (ESK-IN) has been approved by the Food and Drug Administration and the European Medicines Agency for the treatment of TRD in combination with other antidepressants. To assess the effectiveness and tolerability of a...

Esketamine vs. placebo combined with erector spinae plane block vs. intercostal nerve block on quality of recovery following thoracoscopic lung resection: a randomized controlled factorial trial.

International Journal of Surgery 2025 Jing-Hui Hu, Zhang-Zhen Zhong, Hai-Jing Shi et al. 21 citations

Multimodal analgesic strategy is pivotal for enhanced recovery after surgery. The objective of this trial was to assess the effect of subanesthetic esketamine vs. placebo combined with erector spinae plane block (ESPB) vs. intercostal nerve block (ICNB) on postoperative recovery following thoracoscopic lung resection. This randomized, controlled, 2×2 factorial trial was conducted at a...

Efficacy and safety of esketamine versus propofol in electroconvulsive therapy for treatment-resistant depression: A randomized, double-blind, controlled, non-inferiority trial.

Journal of Affective Disorders 2025 Qing-Bin Zeng, De-Cheng Zou, Xing-Bing Huang et al. 12 citations

Electroconvulsive therapy (ECT) is a commonly used alternative for treatment-resistant depression (TRD). Although esketamine has a rapid pharmacological antidepressant action, it has not been studied as an ECT anesthetic. The objective of this study was to compare the efficacy and safety of esketamine with propofol when both are used as ECT anesthetic agents. Forty patients with TRD were...

DOI: 10.1016/j.jad.2024.09.038 (opens in new tab) Full text (opens in new tab) Esketamine Propofol Electroconvulsive therapy ect Shock therapy +7

Electroconvulsive therapy combined with esketamine improved depression through PI3K/AKT/GLT-1 pathway.

Journal of Affective Disorders 2025 Xiangyang Zang, Jingting Zhang, Jingping Hu et al. 16 citations

Neuron excitotoxic damage induced by extracellular glutamate accumulation pathologically is one of the main mechanisms of depression. Glutamate transporter-1 (GLT-1) expressed in astrocyte is responsible for glutamate clearance to maintain glutamate balance. Electroconvulsive therapy (ECT) is prevalently recommended for severe depression due to its significant anti-depressant effect. Esketamine...

Modulation of the endocannabinoid system by (S)-ketamine in an animal model of depression.

Pharmacological Research 2025 Nicole R Silva, Shokouh Arjmand, Luana B Domingos et al. 6 citations

Ketamine (KET) is recognized as rapid-acting antidepressant, but its mechanisms of action remain elusive. Considering the role of endocannabinoids (eCB) in stress and depression, we investigated if S-KET antidepressant effects involve the regulation of the eCB system using an established rat model of depression based on selective breeding: the Flinders Sensitive Line (FSL) and their controls,...

DOI: 10.1016/j.phrs.2024.107545 (opens in new tab) Full text (opens in new tab) Esketamine Flinders sensitive line Lipidome Ketamine therapy s-ketamine +4

Is there a risk of addiction to ketamine during the treatment of depression? A systematic review of available literature.

Journal of Psychopharmacology 2025 Gianmarco Ingrosso, Anthony J. Cleare, Mario F Juruena 20 citations

Ketamine has demonstrated both rapid and sustained efficacy in treating depression, especially in treatment-resistant cases. However, concerns regarding the addictive potential of ketamine during long-term depression treatment persist among clinicians. This review aimed to summarise the evidence on addiction phenomena associated with ketamine treatment of depression. A comprehensive search was...

Impact of social determinants of health on esketamine nasal spray initiation among patients with treatment-resistant depression in the United States.

Journal of managed care & specialty pharmacy 2025 Kristin Clemens, Maryia Zhdanava, Amanda Teeple et al. 4 citations

Disparities in mental health care access and health outcomes based on sociodemographic factors in the United States have been extensively documented. However, there is limited knowledge regarding these socioeconomic factors with respect to initiation of esketamine nasal spray, a novel therapy for treatment-resistant depression (TRD). To evaluate the association of socioeconomic factors with the...

DOI: 10.18553/jmcp.2025.24240 (opens in new tab) Full text (opens in new tab) Mental health Healthcare disparities Depression treatment Socioeconomic status +1

Effects of repeated intravenous esketamine administration on affective biases.

The World Journal of Biological Psychiatry 2025 Christine Reif-Leonhard, Shannon N Millard, Dorsa Ferdowssian et al. 3 citations

While neuropsychological effects of conventional antidepressants are well-documented, more research is needed for rapid-acting antidepressants. This study examines the effects of esketamine on emotion processing and cognitive functioning, both acutely and sub-chronically. Eighteen treatment-resistant depression (TRD) patients received repeated intravenous esketamine infusions. Mood state was...

DOI: 10.1080/15622975.2024.2441304 (opens in new tab) Full text (opens in new tab) Ema Rapid acting antidepressant Dosing Prediction +8

Esketamine Treatment Trajectory of Patients with Treatment-Resistant Depression in the Mid and Long-Term Run: Data from REAL-ESK Study Group.

Current Neuropharmacology 2025 Gianluca Rosso, Giacomo d'Andrea, Stefano Barlati et al. 23 citations

Data on long-term treatment with Esketamine Nasal Spray (ESKNS) in real-world patients with treatment resistant depression (TRD) is scarce. The primary aim of the study is to evaluate the effectiveness and tolerability of ESK-NS treatment at 6 and 12-month follow-ups. This is part of an observational, retrospective, multicentric Italian study (REAL-ESK study). Subjects for the present study...

Is there a risk of esketamine misuse in clinical practice?

Therapeutic advances in drug safety 2025 Carlos Roncero, Milton Merizalde-Torres, Néstor Szerman et al. 11 citations

In 2019, intranasal esketamine gained approval as a promising therapy for those individuals grappling with treatment-resistant depression. Both clinical trials and real-world studies have underscored its efficacy in alleviating and remitting depressive symptoms, with sustained benefits observed for nearly 4.5 years. As the S-enantiomer of ketamine, esketamine's dosing guidelines and strict...

Effects of esketamine on postoperative pain and inflammatory factors in children undergoing tonsillectomy and adenoidectomy.

Minerva anestesiologica 2025 Yuchang Zhu, Xujian Wang, Lifeng Wang et al. 3 citations

This study aimed to observe the effect of esketamine on postoperative pain and inflammatory factors in children undergoing tonsillectomy and adenoidectomy. Eighty children scheduled for tonsillectomy and adenoidectomy were randomly divided into two groups using a random number table: an esketamine group (S-ketamine group, N.=40) and a control group (control group, N.=40). The primary outcome...

DOI: 10.23736/S0375-9393.24.18277-6 (opens in new tab) Full text (opens in new tab) Pediatric_medicine Pain_management Anesthesiology Surgical_recovery +1

Effective doses of remimazolam and esketamine combined with remifentanil for endotracheal intubation without muscle relaxants in pediatric patients.

Frontiers in Pharmacology 2025 Jinming Chen, Ying Mai, Xiaolei Cheng et al. 5 citations

The combination of remimazolam and esketamine effectively alleviates adverse hemodynamic effects, such as tachycardia and hypertension, during intubation. However, the dosage for achieving optimal intubation conditions when co-administered with remifentanil remains unestablished. Therefore, this study aimed to determine the effective doses of remimazolam and esketamine for endotracheal...

DOI: 10.3389/fphar.2025.1558966 (opens in new tab) Full text (opens in new tab) Esketamine Dixon’s up-and-down method Effective dose Remimazolam +6

Ascorbic Acid and Esketamine for Mental Disorders in Women with Miscarriage: A Randomized Controlled Double-Blind Trial Protocol.

Neuropsychiatric Disease and Treatment 2025 Zhaojuan Ke, Ying Zhang, Binyang Cai et al. 1 citation

Pregnancy leads to vulnerabilities and susceptibilities to mental disorders. Miscarriage, as an adverse pregnancy outcome, and following curettage for treatment, add the risks of further psychiatric disorders, including depression, anxiety, insomnia, etc., and current approaches to prevention are unsatisfactory. Ketamine and its S-enantiomer esketamine can prevent postpartum depression, and...

Effect of Esketamine Compared with Sufentanil Combined with Propofol in Patients Undergoing First Trimester Surgical Abortion: A Randomized, Double-Blinded Clinical Trial.

Drug Design, Development and Therapy 2025 Yingchao Guan, Haochen Wang, Xiaojing Cong et al.

We explored whether esketamine anesthesia during first-trimester surgical abortion can reduce intraoperative hemodynamic fluctuations and improve patients' respiratory function. A total of 197 patients who underwent a first-trimester surgical abortion were included in the analysis. Patients were randomly assigned to either the esketamine anesthesia group (group E, n=98) or sufentanil anesthesia...

Feasibility of Closed-Loop TCI Based on New EEG Baseline in the Presence of Low Dose of Esketamine: A Randomized Controlled Equivalence Trial.

Drug Design, Development and Therapy 2025 Xiaoshan Li, Shengchao Li, Chanyan Xu et al. 3 citations

This research aimed to quantify the impact of low dose of esketamine on BIS and validate the feasibility of closed-loop TCI system based on the new BIS baseline with low dose of esketamine. This study consisted of two phases. The first phase was to quantify the impact of a low dose of esketamine (0.2mg kg-1 bolus, 5μg kg-1 min-1 infusion for 30min) on BIS and establish a new BIS baseline for...

DOI: 10.2147/DDDT.S508264 (opens in new tab) Full text (opens in new tab) Esketamine Closed-loop controlled system Depth of anesthesia New bis baseline +6

Case Report: Successful management of psychogenic non-epileptic seizures with intranasal esketamine.

Frontiers in Psychiatry 2025 Muneeb Hashmi, Padmasini Mugunthan, Priyal Jain et al. 2 citations

Psychogenic non-epileptic seizures (PNES), or functional seizures (FS), are episodes that resemble epileptic seizures but may be psychological in origin. Unlike epileptic seizures, which are linked to abnormal electrical activity in the brain, functional seizures may be associated with psychological and/or physical distress, and do not show the same electrical patterns on an...

Effects of Esketamine Versus Remifentanil on Hemodynamics and Prognosis in Patients with Septic Shock Receiving Invasive Mechanical Ventilation: A Randomized Controlled Trial.

Drug Design, Development and Therapy 2025 Yuting Li, Hongxiang Li, Feng Zhang et al. 3 citations

Analgesics and sedatives may affect the hemodynamics of patients with septic shock and produce adverse reactions. The purpose of this study is to compare the hemodynamic effects and prognosis of esketamine and remifentanil in combination with propofol in patients with septic shock receiving invasive mechanical ventilation. In this single-center, prospective, randomized, controlled pilot study,...

DOI: 10.2147/DDDT.S520252 (opens in new tab) Full text (opens in new tab) Esketamine Critical care medicine Invasive mechanical ventilation Norepinephrine +4